Trends
Medical devices industry venture financing deals in Asia-Pacific- Jan 2022
Total medical devices industry venture financing deals worth $585.7m were announced in Asia-Pacific in January 2022, led by $100m venture financing of Yikun Bio, according to GlobalData’s deals database.
The value marked a decrease of 18.4% over the previous month of $717.55m and a rise of 7.3% when compared with the last 12-month average of $546.14m.
Asia-Pacific held a 25.14% share of the global medical devices industry venture financing deal value that totalled $2.33bn in January 2022. With a 24.61% share and deals worth $573.33m, China was the top country in Asia-Pacific’s venture financing deal value across medical devices industry.
In terms of venture financing deal activity, Asia-Pacific recorded 41 deals during January 2022, marking an increase of 7.89% over the previous month and a rise of 28.13% over the 12-month average. China recorded 32 deals during the month.
The top five medical devices industry venture financing deals accounted for 74.5% of the overall value during January 2022.
The combined value of the top five medical devices venture financing deals stood at $436.36m, against the overall value of $585.7m recorded for the month.
The top five medical devices industry venture financing deals of January 2022 tracked by GlobalData were:
- Eli Lilly Asia Fund (LAV),Morningside Ventures,PerkinElmer Ventures,Sequoia China Fund and Yuanhe Holdings $100m venture financing deal with Yikun Bio
- The $100m venture financing of VIRTUE Diagnostics (Suzhou) by Lilly Asia ventures,Morningside Ventures,Oriza Holdings,PerkinElmer Ventures and Sequoia China Investment Management
- China Life Science and Technology Innovation Fund,CPE Yuanfeng,Jianfa Xinxing,Jiangu Capital,Jingming Capital,Luxin Venture Capital and Qianhai Fund of Funds $78.79m venture financing deal with Shenzhen Silicon Biomimetic Technology
- The $78.79m venture financing of Shenzhen Sibionics Technology by C&D International Investment Group,China Life Innovation Fund,CPE Funds Management,JD Investment (HK),Jingming Capital,Qianhai FOF and Return backer Lucion
- CPE Yuanfeng,Guoshou science and Innovation Fund,Jingming Capital and Luxin Venture Capital Group $78.79m venture financing deal with Shenzhen SiliconBased Bionic Technology
Medical Device Network